Inhaled Prophylactic Heparin in Ventilator Associated Pneumonia Prevention (IPHIVAP)

Phase 2

Recruiting

• Conditions: Ventilator Associated Pneumonia; Respiratory - Other respiratory disorders / diseases; Infection - Studies of infection and infectious agents

• Registration Number: ACTRN12612000038897
• Lead Sponsor: A/Prof Robert Boots

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-09
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 914

Inclusion Criteria

Non-invasively mechanically ventilated for < 24hours prior to intubation
No previous mechanical ventilation

Exclusion Criteria

1.Pregancy
2.Aged less than 18 years of age
3.Patients with previous known sensitivity to heparin (any formulation or route) including heparin induced thrombocytopenia
4.Any contraindication to routine prophylaxis for deep vein thrombosis using subcutaneous heparin
5.Presence of a coagulopathy including platelet dysfunction thought to be of clinical significance of any type on admission considered to be a contraindication to routine prophylaxis for deep vein thrombosis using subcutaneous heparin
6.Patients receiving any other type of systemic full anticoagulation
7.Patients transferred from another intensive care unit with more than 48 hours of mechanical ventilation before entering into the present study.

Patients receiving routine subcutaneous thromboembolism prophylaxis (= 15,000/units day) or heparin as part of continuous dialysis therapy where systemic anticoagulation is not required are suitable for inclusion but enrolled patients must be withdrawn from the study upon the need for systemic full anticoagulation or bleeding considered due to the effects of the inhaled heparin by the treating consultant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified